Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?
- 1Cardiovascular Division, The George Institute for Global Health, Sydney, Australia
- Correspondence to Fiona Turnbull
Cardiovascular Division, The George Institute for Global Health, Level 10, KGV Building, RPAH, Missenden Rd, Camperdown, New South Wales 2050, Australia;
The majority of patients with diabetes continue to die from cardiovascular causes. The degree to which improved glucose control could help to address this risk has been examined in recent large trials1,–,3 comparing intensive with usual blood glucose-lowering strategies. This meta-analysis pools the findings from these recent trials as well as several older trials with the aim of defining the effects of intensive control on mortality, cardiovascular events and microvascular events in patients with type 2 diabetes.
Boussageon et al conducted a pooled analysis using published data from 13 trials selected on the basis of having an intensive glucose-lowering treatment arm compared with either a ‘standard’ …